Daniel Baker: Well, as I said, our goal is to grow, and that’s why we’re adding the capacity. And we have several different segments that we serve. So the test capacity is in the business that the industrial and medical business, which is our core business. And then we have the lumpy anti-tamper business that Joe alluded to. So I think the cycles that you’re looking at are not indicating a slowdown in business as much as some of the lumpiness that our business has. And we’re structured as you probably know, that we’re pretty flexible. We have a lot of equipment. We work on making sure that we have adequate capacity across the board so that we can handle increases in business that we avoid bottlenecks and then we invest well in advance of — to prevent bottlenecks.
So that’s why we — the equipment that we have now are investments that we committed to a year ago or more. So we’re very optimistic about the future, and we’re investing in making sure that we can be a growth company.
Unidentified Analyst : Okay. Thank you. And then just one other aspect. You renewed the Abbott contract. Is there anything you can tell us — does that imply that they’re just going to continue ordering as they have in the past? Or is there a lot of potential increase in business in that renewal?
Daniel Baker: So yes, we try not to speak for Abbott. But we certainly see that we have a strong benefit proposition in providing parts for their medical devices. And these are medical devices where the long-term trends are favorable, sometimes in the short term, as Joe alluded to, like in the past quarter, revenues were down a bit. But the long-term prospects are very good for those. The demographics are — we’re all getting older. We’re going to need pacemakers and other medical devices. The — we’re starting to see a recovery in health care from the slowdown for discretionary health care through the pandemic. So as you probably saw, there was an article in our local paper, the Star Tribune about the increase in health care services that we’re seeing here in Minnesota and throughout the country.
So we certainly see the trends as very positive, but it’s a business that has a fair amount of inventory in the chain, as you would expect, for a life support medical device and it can be somewhat cyclical in the near term and sometimes factors beyond our control impact the business in the near term. So things like new model introductions, competitive introductions, FDA approvals, treatment practice for heart failure and other conditions. But in the long term, we see this as a very good business where we have a strong benefit proposition and where there’s good growth potential.
Unidentified Analyst : So probably, the renewal is just sort of a general agreement. It’s not product specific. Is it makes sense?
Daniel Baker: Well, it is product specific, but it’s an agreement of…
Unidentified Analyst : From your standpoint, is it product specific from their standpoint, certain of their end products?
